Literature DB >> 15989578

Olanzapine (Zyprexa):characteristics of a new antipsychotic.

C A Tamminga1, J M Kane.   

Abstract

Olanzapine is a thienobenzodiszepine antipsychotic,which exerts broad-spectrum receptor antagonism in the central nervous system.It demonstrates regionally selective dopamine antagonist activity as measured with the depolarisation block model and fos activation paradigm. Early in vivo imaging studies suggest a relatively low D2 occupancy in th striatum (69%) with a higher 5-HT2 occupancy in the cortex (84%) of 10 mg.Its pharmaco-kinetics are dose-proportional; Tmax is 5 h and the elimination half-life is 31 h (range:21-54 h). Efficacy studies show equivalent antipsychotic efficacy to haloperidol with the possibility of superior efficacy on negative symptoms and depression. Motor side-effects are minimal with mild akathisia emerging at the highest doses; non-motor side-effects are also minimal. Olanzapine is a highly effective antipsychotic drug with minimal side-effects. It will be an important new drug for treating schizophrenia.

Entities:  

Year:  1997        PMID: 15989578     DOI: 10.1517/13543784.6.11.1743

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  4 in total

1.  The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.

Authors:  Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010-06-16       Impact factor: 4.418

2.  Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms.

Authors:  Nagi Idris; Jo Neill; Ben Grayson; Benny Bang-Andersen; Louise M Witten; Lise Tøttrup Brennum; Jørn Arnt
Journal:  Psychopharmacology (Berl)       Date:  2009-10-23       Impact factor: 4.530

3.  Treatments for chronic psychosis.

Authors:  C A Tamminga; A C Lahti
Journal:  Dialogues Clin Neurosci       Date:  2001-12       Impact factor: 5.986

Review 4.  Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.

Authors:  Paula Soria-Chacartegui; Gonzalo Villapalos-García; Pablo Zubiaur; Francisco Abad-Santos; Dora Koller
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.